Biopharmaceutical company Soligenix has secured a contract worth $6.4m from the US Department of Health and Human Service's National Institutes of Health (NIH), for the advanced preclinical development of OrbeShield (oral beclomethasone ...
The US FDA has granted Soligenix fast track designation for OrbeShield for the reduction of mortality associated with gastrointestinal acute radiation syndrome (GI ARS). The oral beclomethasone 17,21-dipropionate (oral BDP) earlier ...
Tags: US FDA, Soligenix, fast track designation, OrbeShield